Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)-Reference-Cited by-同舟云学术

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)

Published:2018-12 Issue: Volume:206 Page:11-23
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Cannon Christopher P.,McGuire Darren K.,Pratley Richard,Dagogo-Jack Sam,Mancuso James,Huyck Susan,Charbonnel Bernard,Shih Weichung J.,Gallo Silvina,Masiukiewicz Urszula,Golm Gregory,Cosentino Francesco,Lauring Brett,Terra Steven G.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference30 articles.

1. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies;Sarwar;Lancet,2010

2. Heart disease and stroke statistics – 2011 update: a report from the American Heart Association;Roger;Circulation,2011

3. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes;Green;N Engl J Med,2015

4. Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54;Bhatt;J Am Coll Cardiol,2016

5. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

Cited by 164 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV;Diabetes, Obesity and Metabolism;2024-09-02

2. Generalizability and treatment with sodium-glucose co-trasporter-2 inhibitors (SGLT2i) among patients with type 2 diabetes: an assessment using an Italian primary care database;Acta Diabetologica;2024-08-29

3. Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial;Diabetes, Obesity and Metabolism;2024-06-05

4. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes;Cochrane Database of Systematic Reviews;2024-05-21

5. Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis;Acta Diabetologica;2024-04-18